Excel PharmaStudies

PPD Paying Cash for Acquisitions, Shelling Out $77M for BioDuro

Monday, December 7, 2009

Wilmington, N.C.-based PPD, a global contract research organization (CRO), is spending its cash hoard in a buying spree to “dominate” the Asia-Pacific region. The CRO doled out $77 million for its latest acquisition of BioDuro, a drug discovery outsourcing company focused on integrated drug discovery programs and services. The deal was completed last week just a couple weeks after it paid cash for another CRO in China. 

[Read More]

PPD Continues China Expansion with Deal to Acquire Drug Discovery Company BioDuro

Thursday, November 19, 2009

Less than a month after announcing its acquisition of China-based contract research organization (CRO) Excel PharmaStudies and plans to dominate the Asia-Pacific region,PPD, the Wilmington, N.C.-based global CRO has signed an agreement to acquire BioDuro LLC, a drug discovery outsourcing company. The acquisition of the 660-employee company will expand PPD’s drug development capabilities in China.  

[Read More]

PPD to Buy China-Based Excel PharmaStudies, Spin Off Compound Partnering

Monday, November 2, 2009

Signaling a major strategic shift, PPD is focusing on Asia-Pacific—China in particular. The company has made a big move in the region by entering into an agreement to acquire Excel PharmaStudies, one of the largest contract research organizations (CROs) in China, which will provide PPD additional capacity in China’s rapidly growing pharmaceutical market. PPD also plans to spin off its compound partnering business from its core CRO work and invest $100 million in Celtic Therapeutics.

[Read More]

Rural Population Key to China’s Clinical Research Market

Friday, November 21, 2008

In his presentation at China Trials 2008 in Shanghai, “Conducting Global Post-Marketing Surveillance Studies in China—Opportunity and Practical Issues,” Mark Engel, president and chairman of Excel PharmaStudies, a large China-based contract research organization, identified two megatrends that will drive post-marketing surveillance studies to China: the rapid aging of its population and its increasingly insured rural population.

[Read More]